Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

April 22, 2025 updated by: Alaa Mahmoud Ahmed Shawqy Mahmoud, Future University in Egypt

Efficacy of Losartan in the Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients.

Paclitaxel-induced peripheral neuropathy (PIPN) is one of the most dose-limiting side effects; it causes patients discomfort and pain and sometimes causes the termination of the chemotherapy cycles, leading to treatment failure. A lot of interventions have been tried to prevent PIPN, ensure complete administration of the chemotherapy cycles, and increase the survival rate. One of the promising interventions in the prevention of PIPN is Losartan. Losartan is an angiotensin receptor blocker (ARBs) and is used to treat hypertensive patients. There is strong evidence from different preclinical studies and retrospective cohort studies that Losartan has a neuroprotective effect.

The purpose of our study is to investigate the efficacy of Losartan in the prevention of peripheral neuropathy associated with Paclitaxel treatment in Breast Cancer patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

84

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Cairo, Egypt
        • Breast Cancer Comprehensive Center of the National Cancer Institute, Cairo University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Females older than 18 years diagnosed with biopsy-confirmed breast cancer (Early breast cancer eligible for adjuvant or neoadjuvant) who are scheduled to receive paclitaxel 80 mg/m2.

Exclusion Criteria:

  • Known hypersensitivity to Losartan.
  • Not Known Hypertensive patients
  • Not Known Diabetic patients
  • Treatment with Losartan/ARBs/ACE-I prior to the study.
  • Previous neuropathy
  • Renal impairment (Serum creatinine > 2 mg/dl)
  • Significant liver disease: liver enzymes 2 folds the upper normal limit
  • Metastatic breast cancer
  • Pregnancy or lactation
  • Taking other medication for neuropathic pain
  • Significant Hypotension

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control arm
These patients will receive standard-of-care management for chemotherapy-induced nausea and vomiting
Experimental: Intervention arm
These patients will receive standard-of-care management for chemotherapy-induced nausea and vomiting plus losartan 100mg
Drug: Losartan
Using losartan to prevent paclitaxel-induced peripheral neuropathy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Development of paclitaxel-induced peripheral neuropathy
Time Frame: 12 weeks
Incidence and grading of paclitaxel-induced peripheral neuropathy (PIPN)
12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient QOL
Time Frame: 12 weeks
Patient quality of life will be assessed by Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX)
12 weeks
Pain Severity
Time Frame: 12 Weeks
Pain intensity will be assessed through Visaul Analogue Scale Scale 0-10
12 Weeks
Serum biomarker
Time Frame: 12 weeks
Level of Nerve growth factor (NGF) in Serum
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Future University in Egypt

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 12, 2023

Primary Completion (Actual)

March 30, 2025

Study Completion (Actual)

March 30, 2025

Study Registration Dates

First Submitted

November 11, 2023

First Submitted That Met QC Criteria

November 15, 2023

First Posted (Actual)

November 18, 2023

Study Record Updates

Last Update Posted (Actual)

April 24, 2025

Last Update Submitted That Met QC Criteria

April 22, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • REC-FPFUE-30/2023

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peripheral Neuropathy Due to Chemotherapy

Clinical Trials on Losartan

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe